Ariana Pelosci

Results from the phase 1/2 STARTRK-NG and phase 2 TAPISTRY trials led to the approval of entrectinib for patients who are 1 month or older with solid tumors.

Results from the phase 3 FLAMES trial show an improved progression-free survival benefit with senaparib monotherapy vs placebo across all pre-specified patient subgroups with newly diagnosed, advanced ovarian cancer.

Those with resectable non–small cell lung cancer can now receive neoadjuvant treatment with pembrolizumab and chemotherapy followed by adjuvant pembrolizumab after approval by the FDA.

Results from the phase 3 FLAURA2 trial allowed for the combination of osimertinib plus chemotherapy to be submitted for priority review.

Members of the committee reviewed findings from the phase 3 CodeBreaK200 trial, assessing the benefit of sotorasib in KRAS G12C–mutant non–small cell lung cancer.

When teclistamab was evaluated in a real-world setting, investigators determined that efficacy was similar between that and the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.

Lucio N. Gordan, MD, reviews how the chemotherapy drug shortages have led to price gouging, potentially making treatment unavailable to patients.

Patients with myelofibrosis and anemia can now receive treatment with momelotinib following the agent’s approval by the FDA based on results from the phase 3 MOMENTUM trial.

Prescribing information has been updated to include temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma or refractory anaplastic astrocytoma.

Results from the phase 1/2 BEXMAB study assessing bexmarilimab show promising activity in patients with acute myeloid leukemia.

Luspatercept, the use of which is supported by results from the phase 3 COMMANDS trial presented at 2023 ASCO, is now available for patients with low-risk myelodysplastic syndrome and anemia.

At an Around the Practice, experts from Emory University gathered to discuss treatment options for patients with multiple myeloma who are transplant-eligible or ineligible.

Patients with complete lymph node response, partial lymph node response, or negative lymph node response were less likely to experience recurrence and increased survival in esophageal adenocarcinoma.

The primary end point of progression-free survival was met in the phase 3 LITESPARK-005 trial investigating belzutifan vs everolimus in patients with renal cell carcinoma.

Data indicate that it may be safe to pause endocrine therapy for patients to attempt to conceive, and experts in the space review how it has impacted treatment strategies.

Physician burnout is not just a phase, but rather a mental health issue that has made itself well-known in the medical community, with many clinicians trying to find strategies to cope with it.

Elranatamab-bcmm is now approved for patients with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Amid the recent cisplatin shortages across the United States, a pharmacy expert discusses how the treatment of bladder cancer has been affected, especially in the muscle-invasive subtype.

Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.

Patients with metastatic RET fusion-positive non–small cell lung cancer may now be treated with pralsetinib, which has been granted regular approval by the FDA.

Results from the phase 3 SUNLIGHT trial support the approval of trifluridine/tipiracil plus bevacizumab in patients with previously treated, metastatic colorectal cancer.

Experts in the genitourinary and gynecology fields discuss how they have adapted and adjusted treatment for their patients amid the United States’ shortage of cisplatin and carboplatin.

Sandra P. D’Angelo, MD, reviews current treatments in sarcoma, and how she interacts with her multidisciplinary counterparts to offer the best care to her patients.

Results from the phase 1/2 NP30179 trial led the European Commission to grant conditional marketing authorization to patients with relapsed/refractory diffuse large B-cell lymphoma.

Blinatumomab has been granted full approval by the FDA for patients with B-cell acute lymphoblastic leukemia and minimal residual disease of 0.01% or more.

Results from the phase 1/2 NP30179 analyzing glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma and large B-cell lymphoma are reported to have helped lead to its approval.

Results from the phase 2 DARIA trial found an improved overall response rate in patients given daratumumab, ixazomib, and dexamethasone with relapsed/refractory multiple myeloma who were previously treated with lenalidomide.

Treatment with patritumab deruxtecan appears to yield improved responses in patients who have been heavily pretreated for metastatic breast cancer.

Results from the phase 2b HERIZON-BTC-01 trial show positive efficacy and safety responses in patients with locally advanced, unresectable or metastatic biliary tract cancer.

Patients with BRCA-mutated metastatic castration-resistant prostate cancer can now receive treatment with olaparib plus abiraterone/prednisone or prednisolone following the combination’s approval by the FDA.